The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis

Journal of Clinical Investigation

Volumn 92, Issue 1, 1993, Pages 411-417

  Tsutsumi, K ^a   Inoue, Y ^a   Shima, A ^a   Iwasaki, K ^a   Kawamura, M ^a   Murase, T ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

atherosclerosis; high density lipoprotein cholesterol; hypertriglyceridemia; lipoprotein lipase; NO 1886

Indexed keywords

4 DIETHOXYPHOSPHORYLMETHYL N (4 BROMO 2 CYANOPHENYL) BENZAMIDE; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; BENZAMIDE DERIVATIVE; COMPLEMENTARY DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; MESSENGER RNA; POLYCLONAL ANTIBODY; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; AUTORADIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE; HISTOPATHOLOGY; INTRAGASTRIC DRUG ADMINISTRATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

EID: 0027260912     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI116582     Document Type: Article

References (0)